Financial Performance - The company expects a net profit of approximately -18 million CNY for the year 2025, representing a decline of 2,319.35% compared to the same period last year[5]. - The projected operating revenue for 2025 is between 480 million CNY and 640 million CNY, compared to 418.96 million CNY in the previous year[5]. - The financial data presented is preliminary and will be detailed in the annual report for 2025[9]. Operational Changes - The company has completed the delivery of the CRRT business held by NKS, which is expected to impact operational performance due to integration and organizational adjustments[8]. - The company plans to account for potential administrative penalties as indicated in the notice received from the Ningbo Market Supervision Administration[8]. Risk Factors - The company has experienced increased foreign exchange losses due to fluctuations in the USD exchange rate[8]. - Inventory levels have expanded year-on-year, leading to an increase in inventory impairment provisions compared to the previous year[8]. - Investors are advised to make cautious decisions and be aware of investment risks[10]. Communication and Compliance - The company has communicated with the accounting firm regarding the preliminary financial estimates, with no significant discrepancies reported[6]. - The company will provide further updates and disclosures as required by regulatory authorities[9].
天益医疗(301097) - 2025 Q4 - 年度业绩预告